Detalhe da pesquisa
1.
Ventricular arrhythmias and sudden death events following acalabrutinib initiation.
Blood
; 140(20): 2142-2145, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917449
2.
Hypertension and incident cardiovascular events following ibrutinib initiation.
Blood
; 134(22): 1919-1928, 2019 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582362
3.
Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
J Oncol Pharm Pract
; 25(3): 567-576, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29298625
4.
A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
J Oncol Pharm Pract
; 25(4): 793-800, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29460705
5.
Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
J Oncol Pharm Pract
; 22(3): 430-6, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26152702
6.
Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib.
Br J Haematol
; 187(3): 399-402, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31531846
7.
A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
Leuk Lymphoma
; : 1-7, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648546
8.
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review.
JACC CardioOncol
; 5(5): 570-590, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37969643
9.
Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity.
JAMA Oncol
; 9(4): 552-555, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729480
10.
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation.
J Hematol Oncol
; 15(1): 92, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35836241
11.
Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists.
Blood Adv
; 4(19): 4860-4863, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33031541
12.
Managing Addiction: Guidelines for Patients With Cancer.
Clin J Oncol Nurs
; 23(6): 655-658, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730608
13.
Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders.
Blood Adv
; 7(14): 3431-3434, 2023 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877766
14.
Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy.
Leukemia
; 37(7): 1588, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37231141
15.
Evaluation of bleeding events in patients receiving acalabrutinib therapy.
Leukemia
; 37(7): 1554-1557, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932166
16.
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.
Blood Adv
; 1(20): 1739-1748, 2017 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296820
17.
Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
Leuk Lymphoma
; 62(3): 716-721, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33210562
18.
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.
Leukemia
; 33(10): 2527-2530, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31086260
19.
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.
J Am Coll Cardiol
; 72(6): 697-698, 2018 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30072003